{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:35:30Z","timestamp":1765805730705},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/adm.0b013e31829b1a6c","type":"journal-article","created":{"date-parts":[[2013,7,27]],"date-time":"2013-07-27T11:14:08Z","timestamp":1374923648000},"page":"320-324","source":"Crossref","is-referenced-by-count":16,"title":["A Unique Model for Treating Chronic Hepatitis C in Patients With Psychiatric Disorders, Substance Abuse, and\/or Housing Instability"],"prefix":"10.1097","volume":"7","author":[{"given":"Cheryl J.","family":"Ho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Fredericks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara L.","family":"Doorley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"10","key":"R1-3-20210126","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"12","key":"R2-3-20210126","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2893.2012.01648.x","article-title":"Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.","volume":"19","author":"Charlebois","year":"2012","journal-title":"J Viral Hepat"},{"issue":"4","key":"R3-3-20210126","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00004836-200204000-00021","article-title":"Viral hepatitis and other infectious diseases in a homeless population.","volume":"34","author":"Cheung","year":"2002","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"R5-3-20210126","first-page":"211","article-title":"Is it justifiable to withhold treatment for hepatitis C from illicit-drug users N Engl J M","volume":"345","author":"Edlin","year":"2001","journal-title":"ed"},{"issue":"11","key":"R6-3-20210126","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s10620-006-9669-0","article-title":"High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities.","volume":"52","author":"Evon","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"13","key":"R7-3-20210126","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"R8-3-20210126","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MEG.0b013e32832a8c4c","article-title":"Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support.","volume":"22","author":"Grebely","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"R9-3-20210126","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-2a and ribavirin combination therapy in chronic hepatitis C.","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"10","key":"R10-3-20210126","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1572-0241.2006.00731.x","article-title":"Integrated psychiatricmedical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes.","volume":"101","author":"Knott","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"suppl 5","key":"R11-3-20210126","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1086\/427450","article-title":"Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.","volume":"40","author":"Litwin","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"9286","key":"R12-3-20210126","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"9791","key":"R13-3-20210126","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"R14-3-20210126","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1525-1497.2002.10415.x","article-title":"Risk factors for hepatitis C virus infection among homeless adults.","volume":"17","author":"Nyamathi","year":"2002","journal-title":"J Gen Intern Med"},{"issue":"2","key":"R15-3-20210126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.","volume":"18","author":"Robaeys","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"R16-3-20210126","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in difficult-to-treat psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"R17-3-20210126","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-157-2-201207170-00006","article-title":"Escitalopram for the prevention of peginterferon-2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.","volume":"157","author":"Schaefer","year":"2012","journal-title":"Ann Intern Med"},{"issue":"2","key":"R18-3-20210126","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"R19-3-20210126","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jsat.2012.08.007","article-title":"Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.","volume":"43","author":"Stein","year":"2012","journal-title":"J Subst Abuse Treat"},{"issue":"suppl 5","key":"R20-3-20210126","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1086\/427447","article-title":"Treating hepatitis C virus infection in active substance users.","volume":"40","author":"Sylvestre","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R21-3-20210126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.","volume":"29","author":"Sylvestre","year":"2005","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"R22-3-20210126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archinternmed.2010.511","article-title":"Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006.","volume":"171","author":"Williams","year":"2011","journal-title":"Arch Intern Med"},{"issue":"4","key":"R23-3-20210126","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.20132","article-title":"Hepatitis C virus-infected patients report communication problems with physicians.","volume":"39","author":"Zickmund","year":"2004","journal-title":"Hepatology"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0b013e31829b1a6c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:08:39Z","timestamp":1620943719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01271255-201309000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0b013e31829b1a6c","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}